

# IN THE CLAIMS


Amend Claims 28-37 as shown below:

Claim 28. (currently amended) A method of treating androgenic alopecia consisting essentially of transdermally administering to a person in need of such treatment a therapeutically effective amount of a 5alpha-reductase 2 inhibitor as the active ingredient.

Claim 29. (previously presented) The method according to Claim 28, wherein androgenic alopecia is male pattern baldness.

Claim 30. (previously presented) The method according to Claim 28, wherein the 5alpha-reductase 2 inhibitor is transdermally administered by a transdermal skin patch.

Claim 31. (previously presented) The method according to Claim 28, wherein the 5alpha-reductase 2 inhibitor has the structural formula I:



or a pharmaceutically acceptable salt thereof wherein:

R<sup>1</sup> is hydrogen, methyl or ethyl;


R<sup>2</sup> is a hydrocarbon radical selected from straight and branched chain alkyl of from 1-12 carbons or monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halogen substituents selected from Cl, F and Br;

R' is hydrogen or methyl;

R'' is hydrogen or β-methyl; and

R''' is hydrogen, α-methyl or β-methyl.

Claim 32. (previously presented) The method according to Claim 28, wherein the 5 $\alpha$ -reductase 2 inhibitor has the structural formula II:



or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup> is hydrogen or methyl; and

R<sup>3</sup> is branched chain alkyl of from 4 to 8 carbons.

Claim 33. (currently amended) A method of treating androgenic alopecia consisting essentially of transdermally administering to a person in need of such treatment a therapeutically effective amount of 17 $\beta$ -(N-tert-butylcarbamoyl)-4-aza-5 $\alpha$ -androst-1-ene-3-one as the active ingredient.

Claim 34. (previously presented) The method of Claim 33 wherein androgen alopecia is male pattern baldness.

Claim 35. (previously presented) The method according to Claim 33, wherein the 17 $\beta$ -(N-tert-butylcarbamoyl)-4-aza-5 $\alpha$ -androst-1-ene-3-one inhibitor is transdermally administered by a transdermal skin patch.

Claim 36. (currently amended) A transdermal skin patch consisting essentially of a therapeutically effective amount of a 5  $\alpha$ -reductase 2 inhibitor as the active ingredient.

Claim 37. (previously presented) The transdermal skin patch according to Claim 36 wherein the 5 $\alpha$ -reductase 2 inhibitor is 17 $\beta$ -(N-tert-butylcarbamoyl)-4-aza-5 $\alpha$ -androst-1-ene-3-one.